NEXALIS THERAPEUTICS LTD
ASX:NX1Pharmaceuticals, Biotechnology & Life SciencesToday’s holders own 76.8% of what they think they own, once every option and right converts.
Runway under 2 quarters; options/rights overhang 30% of shares; 1 cash raise in 24 months; since relisting as NX1; prior history under IRX not included
NEXALIS THERAPEUTICS LTD changed its ASX code from IRX in February 2026; all figures cover only the period since that rename. Between February 2026 and February 2026, its latest share-count filing, the ordinary share count stands at 253M shares, a 0.3% increase. One capital raise occurred in the 24-month window, a placement in February 2026 raising A$150K. Options and rights on issue could convert into 76M new shares, equal to 30.2% of the current share count, with none in the money; the nearest expiry is December 2026. The company has under 2 quarters of funding at the recent spend rate. No proposed securities issues are pending.
Quick answers · 2
When did NX1 last raise capital?
The last capital raise in Nexalis Therapeutics's filings is Placement of $150k announced 17 Feb 2026, one of 1 cash raises in 24 months.
When do NX1's options expire?
Unexercised options and rights equal 30.2% of Nexalis Therapeutics's shares on issue; the nearest expiry is Dec 2026.
Shares on issue — last 2 years
Cash runway
Issuance timeline
Latest 5 filings (Appendix 2AThe form a company lodges to have new securities quoted on the ASX. It restates how many of each class are on issue. quoted issues, 3G unquoted, 3H cancellations)
| Date | Form | Security | On issue, per this filing | Source |
|---|---|---|---|---|
| 14 July 2026 | 3G · unquoted | ORDINARY FULLY PAID | 253.0M | Appendix 3G |
| 14 July 2026 | 3H · cancellation | NX1 : ORDINARY FULLY PAID | 253.0M | Appendix 3H |
| 23 Feb 2026 | 2A · quoted issue | NX1 : ORDINARY FULLY PAID | 253.0M | Appendix 2A |
| 17 Feb 2026 | 2A · quoted issue | NX1 : ORDINARY FULLY PAID | 252.3M | Appendix 2A |
| 17 Feb 2026 | 3G · unquoted | ORDINARY FULLY PAID | 246.3M | Appendix 3G |
Securities on issue over time
Ordinary shares and every option and rights class, month by month over two years. The top edge is the fully diluted count.
Capital raises
1 cash raise in the last 24 months · 1 in the last 12 months · counted since relisting as NX1 (16 Feb 2026); prior history under IRX is not included
Forward supply
Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.
Placement capacity
How much stock a company can place without asking holders. Listing Rule 7.1 / 7.1ARule 7.1 lets a company issue up to 15% of its shares in 12 months without a shareholder vote. Rule 7.1A adds 10% for smaller companies whose holders approve it. allows 15% of ordinary securities in any 12 months, and every Appendix 3BNotice that a company proposes to issue new securities, such as a placement. The securities are not on issue until a later filing confirms it. states how much of it an issue uses.
Pending proposed issues
Options & convertible securities
- Price-triggered69.1M · 27.3% of sharesOptions and warrants — they convert when the share price clears their exercise price.
- Condition-triggered7.4M · 2.9% of sharesPerformance and incentive rights — they convert when a hurdle is met, not at a price, and can lapse to nothing.
Exercise price on record: 69.1M priced, 7.4M where the filing never states one. A security with no exercise price is never counted in the money — nothing is paid to convert it, so there is no price for it to be above.
Each figure is the filing’s own count of securities, not a share count — a 2A never states what one security converts into.
At $0.009 today, 0 securities are in the money (0.0% of shares on issue). No more priced supply until 3× today’s price, which takes it to 38.4M (15.2% of shares).
- Priced supply in the money at the price on the axis — the curve, and the only thing on it. Ten prices, sampled: between two of them the true figure lies between the two.
- 7.4M (9.6% of the supply above) states no exercise price at all. It cannot be called in or out of the money at any price, which is why it is hatched rather than plotted.
- 7.5M more carries an exercise price above ten times today’s — off the right of this axis, and in every total on this page.
| Code | Security | Type | Exercise price | Expiry | On issue | Source |
|---|---|---|---|---|---|---|
| NX1AA | Options | Price-triggered | $0.20 | 14 Dec 2026 | 4.0M | Filing |
| NX1AF | Options | Price-triggered | $0.15 | 3 June 2027 | 2.0M | Filing |
| NX1AK | Options | Price-triggered | $0.042 | 22 Dec 2027 | 23.2M | Filing |
| NX1AH | Options | Price-triggered | $0.12 | 7 July 2028 | 1.0M | Filing |
| NX1AI | Options | Price-triggered | $0.12 | 31 Oct 2028 | 500k | Filing |
| NX1AD | Options | Price-triggered | $0.025 | 31 Dec 2029 | 38.4M | Filing |
| NX1AG | Performance rights | Condition-triggered | — | — | 7.4M | Filing |
“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column. For what expires soon across other listed companies, see the options expiry calendar.
Director dealings
| Date | Director | Type | Shares | Options | Other | Value | Source |
|---|---|---|---|---|---|---|---|
| 6 Oct 2026 | Darryl Davies | Sell | — | 2.0M | — | — | 3Y notice |
| 14 July 2026 | Darryl Davies | Sell | 56.3M | 2.0M | — | — | 3Y notice |
| 14 July 2026 | Sean Williams | Other | 2.6M | — | — | — | 3Y notice |
Ownership
Latest announcements
Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 Oct 2026.